Jeil Pharmaceutical to exclusively sell osteoporosis drug Bonviva in Korea

Jeil Pharmaceutical said on Thursday that the company will provide an exclusive domestic supply of osteoporosis treatment Bonviva (ingredients: ibandronate sodium) and Bonviva Plus (ibandronate sodium, cholecalciferol), in Korea.

Jeil signed the exclusive sales deal with Pharmanovia, a U.K. pharmaceutical firm, and began marketing activities, the company said.

Bonviva effectively reduces the risk of bone loss and fracture by repressing osteolysis and bone turnover, and it can be steadily used for women’s osteoporosis treatment, according to Jeil.

Bonviva comes in three types - Bonviva Tab., Bonviva Inj., and Bonviva Plus Tab.